{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'would prevent the subject from completing the study procedures.', 'CONTRAINDICATIONS', '19.', 'Any history of allergy or hypersensitivity to any anticholinergic/muscarinic', 'receptor antagonist, sympathomimetic, lactose/milk protein or magnesium', 'stearate.', 'DIAGNOSTIC ASSESSMENTS AND OTHER CRITERIA', '20.', 'Pulmonary Rehabilitation program: Participation in the acute phase of a', 'pulmonary rehabilitation program within 4 weeks prior to Screening Visit 1.', 'Subjects who are in the maintenance phase of a pulmonary rehabilitation program', 'are not excluded.', '21.', 'Affiliation with investigator sites: Is an investigator, sub-investigator, study', 'coordinator, employee of a participating investigator or study site, or immediate', 'family member of the aforementioned that is involved in this study', '22.', 'Inability to read: In the opinion of the investigator, any subject who is unable to', 'read and/or would not be able to complete questionnaires on the electronic diary.', 'Subjects who fail to meet inclusion and exclusion criteria at the Screening Visit 1 will be', 'considered screen failures and cannot be re-screened.', '5.3.', 'Randomization Criteria', 'In order to be randomized to one of the 3 treatment arms at Visit 2, subjects must have', 'completed the run-in period and must have fulfilled all inclusion and exclusion criteria', 'described in Section 5.1 and Section 5.2. In addition to the following:', 'REQUIRED CRITERIA FOR RANDOMIZATION AND TREATMENT', '1. COPD Exacerbation: Subjects must not have experienced a moderate or severe', 'COPD exacerbation or a lower respiratory tract infection during run-in or at Day 1', '(Visit 2) inclusive. A moderate exacerbation is defined as worsening of symptoms of', 'COPD requiring the use of antibiotics or systemic corticosteroids. A severe', 'exacerbation is defined as worsening symptoms of COPD requiring hospitalization.', '2. CAT score: A CAT score of >10 at Visit 2', '3. Prohibited Medications: No use of any prohibited medications during the run-in', \"period or at Visit 2, including any ICS or ICS/LABA combination. Subject's inhaled\", 'LABA or LAMA medication morning dose must be withheld and discontinued at', 'Visit 2.', '4. Any change to COPD medications: Including dosage and regimen during the run-in', '5. Completion of electronic diary: Must have completed the electronic diary for at', 'least 80% of days during the run-in period', '31']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Subjects who do not meet the required criteria for randomization at Visit 2 will not be', 'randomized.', '5.4.', 'Screening/Baseline/Run-in Failures', 'Pre-screen, screen and run-in failures are defined as follows:', 'Pre-screening failures: A subject, who is assigned a subject number at the Pre-', 'screening Visit 0 but does not have any Screening Visit 1 procedures, will be', 'considered a pre-screen failure.', 'Screening failures: Those subjects that complete at least one Screening Visit 1', 'procedure but do not enter the run-in period.', 'Run-in failures: Those subjects that enter the run-in period but are not randomized', 'to any of the study treatment arms.', 'Subjects who are pre-screen, screen and run-in failure will be recorded in the eCRF. In', 'order to ensure transparent reporting of screen failure subjects, meet the Consolidated', 'Standards of Reporting Trials (CONSORT) publishing requirements, and respond to', 'queries from Regulatory Authorities, a minimal set of screen failure information is', 'required to be recorded in eCRF including demography, screen failure details, eligibility', 'criteria, and serious adverse events (Section 7.4.1).', '5.5.', 'Withdrawal/Stopping Criteria', '5.5.1.', 'Withdrawal from the Study', 'Subjects may be withdrawn from the study at any time by the Investigator if it is', 'considered to be detrimental for them to continue in the study. Reasons for withdrawal', 'from study treatment can include: an AE, clinically significant abnormality, lack of', 'efficacy, sponsor terminated study, pregnancy, or for any other reason.', 'If a subject withdraws from the study, he/she may request destruction of any samples', 'taken, and the investigator must document this in the site study records.', 'A reason for the withdrawal from the study must be captured in the electronic case report', 'form (eCRF).', 'Stopping Criteria', 'A subject must be withdrawn from the study, in consultation with the medical monitor', 'and principal investigator, if any of the following stopping criteria are met:', 'Liver Chemistry: Meets any of the Liver chemistry stopping criteria (See Section', '5.5.3)', 'Note: clinical laboratory assessments are not required for this study. However,', 'laboratory samples may be taken for liver event analysis, if clinically indicated by', 'the study investigator.', 'Pregnancy: Positive pregnancy test (see Appendix 7)', '32']\n\n###\n\n", "completion": "END"}